Skip to content

Optimal effect-site concentration of remifentanil for minimizing cardiovascular changes to nasotracheal intubation during remimazolam anesthesia

Optimal effect-site concentration of remifentanil for minimizing cardiovascular changes to nasotracheal intubation during remimazolam anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007933
Enrollment
50
Registered
2022-11-24
Start date
2022-11-18
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Anesthesia was induced with continuous infusion of remimazolam at a rate of 6mg/kg/hr(0.1mg/kg/hr) until the loss of consciousness (LoC) of the patient. Anesthesia was maintained with 1-2mg/kg/
each patient’s response determined the target Ce of remifentanil administered to the next patient. A response was considered successful if HR and MBP values recorded 1 minute after intubation did not
if they did, a failed response was determined. If a response was successful, the target concentration of remifentanil was lowered by 0.5 ng/mL for the next patient
if a response failed, the target concentration of remifentanil was increased by 0.5 ng/mL.

Sponsors

Pusan National University Dental Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled to undergo oral and maxillofacial surgery American Society of Anesthesiologist Physical Status (ASA PS) 1,2

Exclusion criteria

Exclusion criteria: allergic history (remifentanil or any benzodiazepine drugs)

Design outcomes

Primary

MeasureTime frame
Dose of remifentanil associated 50% probability for adequate depth of anesthesia for nasotracheal intubation

Secondary

MeasureTime frame
Mean arterial pressure, heart rate

Countries

Korea, Republic of

Contacts

Public ContactEun-Ji Choi

Pusan National University Dental Hospital

acej01@naver.com+82-55-360-5370

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026